Search Results

Bristol Myers Squibb announced the first presentation of results from the Phase 3 CheckMate -9DW trial evaluating the dual immunotherapy combination of Opdivo® plus Yervoy® compared to investigator’s choice of lenvatinib or sorafenib as a first-line treatment for patients with unresectable hepatocellular carcinoma.

Bristol Myers Squibb (NYSE: BMY) today announced the Phase 3 CheckMate -9DW trial evaluating Opdivo (nivolumab) plus Yervoy (ipilimumab).

DW Healthcare Partners (“DWHP”) a healthcare-focused private equity firm, announced the closing of its sale of Med-Pharmex Holdings, Inc (“Med-Pharmex”, or the “Company”) to Dechra Pharmaceuticals PLC (“Dechra”). Med-Pharmex is a leading, fully-integrated veterinary pharmaceutical manufacturer focused on developing, manufacturing, and commercializing animal health drugs.

Sirona Biochem Corp. has announced a partnership with Stonegate Healthcare Partners. Stonegate is a leading corporate advisory firm based in Dallas, Texas that offers research driven business development and investor outreach services.

BioMatrix Specialty Infusion Pharmacy (“BioMatrix” or “The Company”) announced today the sale of the majority interests of the company from Acon Investments & Triton Pacific Healthcare to Frazier Healthcare Partners (“Frazier”).